Contains Nonbinding Recommendations

Guidance on Divalproex Sodium

This guidance represents the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Divalproex sodium

Dosage Form; Route: Delayed-release pellets capsule; oral

Recommended Studies: Three studies

1. Type of study: Fasting
   Design: Single-dose, 2-treatment, 2-sequence, 4-period, fully replicated crossover in vivo
   Strength: 125 mg
   Subjects: Normal healthy males and nonpregnant females, general population
   Additional comments: Please evaluate for normal liver function tests prior to dosing with divalproex sodium in bioequivalence studies

2. Type of study: Fed
   Design: Single-dose, 2-treatment, 2-sequence, 4-period, fully replicated crossover in vivo
   Strength: 125 mg
   Subjects: Normal healthy males and nonpregnant females, general population
   Additional comments: Please see comment above

3. Type of study: Fasting sprinkle-in-applesauce
   Design: Single-dose, 2-treatment, 2-sequence, 4-period, fully replicated crossover in vivo
   Strength: 125 mg
   Subjects: Normal healthy males and nonpregnant females, general population
   Additional comments: Please see comment above

Analytes to measure: Valproic Acid in plasma

Bioequivalence based on (90% CI): Valproic Acid

Waiver request of in vivo testing: Not Applicable

Recommended May 2006; Revised Dec 2016
**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

**Explanation:** FDA has concluded that valproic acid is a narrow therapeutic index (NTI) drug based on the following evidence:

- The range between the effective valproic acid concentrations and the concentrations associated with serious toxicity is narrow;
- Sub-optimal doses or concentrations lead to therapeutic failure or severe toxicity;
- Valproic acid is subject to therapeutic monitoring based on pharmacokinetics measures;
- Valproic acid has low-to-moderate within-subject variability.

The study should be a fully replicated crossover design in order to:

- Scale bioequivalence limits to the variability of the reference product; and
- Compare test and reference products’ within-subject variability.

For details about the “Method for Statistical Analysis Using the Reference-Scaled Average Bioequivalence Approach” for NTI drugs, see the guidance on warfarin sodium.